GETI-B 📈 Getinge AB ser. B - Overview
Exchange: ST • Country: Sweden • Currency: SEK • Type: Common Stock • ISIN: SE0000202624
GETI-B: Medical Devices, Hospital Equipment, Sterilization Systems, Patient Monitoring
Getinge AB, a company with a rich history dating back to 1904, specializes in providing a wide range of products and solutions for critical care environments, including operating rooms, intensive-care units, and sterilization departments. The company's operations are segmented into three main areas: Acute Care Therapies, Life Science, and Surgical Workflows. This structure enables Getinge AB to cater to diverse customer needs, offering a broad spectrum of medical equipment and solutions that enhance patient care and outcomes.
The company's product portfolio is extensive, encompassing extracorporeal membrane oxygenation, mechanical ventilation, and mechanical circulatory support, which are crucial for treating critically ill patients. Additionally, Getinge AB offers advanced patient monitoring systems, ICU infrastructure equipment, and patient flow management solutions, all designed to streamline clinical workflows and improve patient care. The company also provides surgical perfusion, endoscopic vessel harvesting, and intra-aortic balloon counterpulsation solutions, as well as operating room infrastructure equipment, anesthesia, and operating room management solutions, further solidifying its position in the healthcare industry.
Getinge AB's offerings extend to sterilization and infection control solutions, including pre-cleaning, cleaning and disinfection, sterilization, and consumables. The company also provides endoscope reprocessing and sterile supply management solutions, ensuring that medical instruments and equipment are properly sanitized and ready for use. Furthermore, Getinge AB offers connected medical devices, bioreactor systems, and terminal sterilization products, which are essential for life science research and development. Its vivarium, biohazardous materials handling, labware cleaning and sterilization, and bioreactor preparation solutions cater to the specific needs of laboratories and research institutions.
With a strong global presence, Getinge AB distributes its products through a network of sales companies, agents, and distributors across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region. This extensive distribution network allows the company to reach a wide customer base, providing timely and effective support to healthcare professionals and organizations worldwide. As a publicly traded company listed on the Stockholm Stock Exchange, Getinge AB is committed to delivering high-quality products and solutions that meet the evolving needs of the healthcare industry, with its common stock (ISIN: SE0000202624) classified under the Health Care Equipment sub-industry.
Additional Sources for GETI-B Stock
GETI-B Stock Overview
Market Cap in USD | 4,172m |
Sector | Healthcare |
Industry | Medical Devices |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception |
GETI-B Stock Ratings
Growth 5y | 1.14% |
Fundamental | 52.7% |
Dividend | 64.0% |
Rel. Strength Industry | -1017 |
Analysts | - |
Fair Price Momentum | 161.95 SEK |
Fair Price DCF | 261.21 SEK |
GETI-B Dividends
Dividend Yield 12m | 2.54% |
Yield on Cost 5y | 2.74% |
Annual Growth 5y | 33.56% |
Payout Consistency | 94.0% |
GETI-B Growth Ratios
Growth Correlation 3m | -88.3% |
Growth Correlation 12m | -39.5% |
Growth Correlation 5y | 13.5% |
CAGR 5y | 1.63% |
CAGR/Mean DD 5y | 0.06 |
Sharpe Ratio 12m | -0.69 |
Alpha | -33.18 |
Beta | 0.36 |
Volatility | 32.70% |
Current Volume | 2302k |
Average Volume 20d | 920.6k |
As of December 21, 2024, the stock is trading at SEK 174.05 with a total of 2,301,956 shares traded.
Over the past week, the price has changed by +0.61%, over one month by +1.34%, over three months by -23.68% and over the past year by -21.37%.
Partly, yes. Based on ValueRay Fundamental Analyses, Getinge AB ser. B (ST:GETI-B) is currently (December 2024) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 52.68 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of GETI-B as of December 2024 is 161.95. This means that GETI-B is currently overvalued and has a potential downside of -6.95%.
Getinge AB ser. B has no consensus analysts rating.
According to ValueRays Forecast Model, GETI-B Getinge AB ser. B will be worth about 175.2 in December 2025. The stock is currently trading at 174.05. This means that the stock has a potential upside of +0.65%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 219.4 | 26.1% |
Analysts Target Price | - | - |
ValueRay Target Price | 175.2 | 0.6% |